Managers / Q2 2024 · view latest →
Aquilo Capital Management, LLC
CIK 0001591986 · ONE LETTERMAN DRIVE, SUITE D4900, BUILDING D, SAN FRANCISCO, CA, 94129 · 415-635-0140
Summary
Aquilo Capital Management, LLC reported $104M in U.S.-listed holdings across 13 positions for Q2 2024.
The portfolio is heavily concentrated: ARWR alone accounts for 22.8% of reported value.
Compared with Q1 2024, the fund opened 3 new positions and exited 0.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 74.9% · $78M
- Other · 12.8% · $13M
- ADR · 12.2% · $13M
Quarter-over-Quarter Changes full breakdown →
vs Q1 2024 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| BCYCBICYCLE THERAPEUTICS PLC | NEW | +156.7K | 156.7K | +$3M | $3M |
| ADICET BIO INC | NEW | +2.53M | 2.53M | +$3M | $3M |
| IMMATICS N.V | NEW | +200.0K | 200.0K | +$2M | $2M |
| RPTXREPARE THERAPEUTICS INC | ADDED | +323.7K | 956.9K | +$175,170 | $3M |
| MERUS N V | TRIMMED | −107.0K | 148.1K | −$3M | $9M |
| BLUEPRINT MEDICINES CORP | TRIMMED | −67.6K | 114.6K | −$5M | $12M |
| SUTRO BIOPHARMA INC | TRIMMED | −403.0K | 762.5K | −$4M | $2M |
| KYMRKYMERA THERAPEUTICS INC | TRIMMED | −60.0K | 328.7K | −$6M | $10M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q2 2024
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | ARWRARROWHEAD PHARMACEUTICALS INhistory → | COM | 22.76% | $24M | 908.5K |
| 2 | BLUEPRINT MEDICINES CORP | COM | 11.91% | $12M | 114.6K |
| 3 | ARVNARVINAS INChistory → | COM | 11.00% | $11M | 428.8K |
| 4 | RGNXREGENXBIO INChistory → | COM | 10.22% | $11M | 906.2K |
| 5 | KYMRKYMERA THERAPEUTICS INChistory → | COM | 9.46% | $10M | 328.7K |
| 6 | SLNSILENCE THERAPEUTICS PLChistory → | ADS | 9.16% | $10M | 500.2K |
| 7 | MERUS N V | COM | 8.45% | $9M | 148.1K |
| 8 | DTILPRECISION BIOSCIENCES INChistory → | COM NEW | 3.58% | $4M | 381.8K |
| 9 | BCYCBICYCLE THERAPEUTICS PLChistory → | SPONSORED ADS | 3.06% | $3M | 156.7K |
| 10 | RPTXREPARE THERAPEUTICS INChistory → | COM | 3.04% | $3M | 956.9K |
| 11 | ADICET BIO INC | COM | 2.95% | $3M | 2.53M |
| 12 | IMMATICS N.V | SHS | 2.24% | $2M | 200.0K |
| 13 | SUTRO BIOPHARMA INC | COM | 2.15% | $2M | 762.5K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q3 2025 | $0 | 1 | Nov 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $0 | 1 | Aug 6, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $56M | 13 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $66M | 15 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $132M | 14 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $104M | 13 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $133M | 10 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $160M | 10 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $110M | 12 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $180M | 13 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $241M | 12 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $266M | 13 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $277M | 15 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $293M | 13 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $680M | 14 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $882M | 14 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $551M | 14 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $385M | 15 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $553M | 17 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $481M | 17 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $945M | 17 | Nov 16, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $496M | 14 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $257M | 14 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $266M | 12 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $142M | 11 | Nov 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $288M | 13 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $226M | 14 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.